January 14, 2013
As the world's number 1 injectable iron supplementation,
Uniferon assists winning pig farmers in the fight against iron
deficiency anaemia in literally all parts of the world.
As a company with an unrivalled focus on quality in all aspects
of the process, we have long seen the positive effects of best
practice strategies in numerous countries, and we are genuinely
proud and excited as more and more countries are allowed access to
Uniferon.
Today, Uniferon is available in all major pig producing
countries in Europe, in the US, China and Russia. And latest, we
have or are preparing launch of our injectable iron supplementation
in as diverse markets as South Africa, the Ukraine and Poland.
In 2013, we will see the rise of new high-potential markets in
countries where large-scale pig productions are present- and one of
our new key areas is Latin America.
"Latin America is a truly exciting market for injectable iron
with Brazil and Mexico as clear frontrunners. These countries in
particular lays ground to skilled and ambitious pig productions
that will benefit greatly from quality iron knowledge, and we are
happy to supply them with Uniferon in the near future. We are
currently finalizing agreements with local partnering companies,
and we will be able to disclose more about this in the very near
future" said Jens Fabricius, Vice President, Marketing &
Business Operations at Pharmacosmos A/S.
As Uniferon moves one step even closer to a total global reach,
we look ahead to a challenging and exciting 2013 with high
optimism.
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.